<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart</h1>

    <table>
      <tr><th>Ticker</th><td>BCDA</td></tr>
      <tr><th>Float</th><td>4.8 M</td></tr>
      <tr><th>IO</th><td>5.45%</td></tr>
      <tr><th>MC</th><td>13.4 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>BioCardia (NASDAQ: BCDA) submitted a Pre-Submission to the FDA under the Q-Submission program seeking alignment on the regulatory pathway and timing for approval of its Helix transendocardial delivery catheter. The filing cites safety and effectiveness data from 15 clinical trials across three cardiac indications and was made under the CardiAMP Cell Therapy System's FDA Breakthrough Designation. The company expects FDA alignment within ~45 days and may follow with a market clearance application. BioCardia states Helix offers superior intramyocardial retention, broader delivery reach, and improved dosing versus other delivery methods and is intended to support future approvals of its autologous and allogeneic cell therapies.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Pre-Submission to FDA completed under Q-Submission program (proactive regulatory engagement).</li><li>Submission supported by data from 15 well-controlled clinical trials across three cardiac indications.</li><li>Filed under CardiAMP FDA Breakthrough Designation, which may accelerate regulatory interactions.</li><li>Company expects FDA alignment within ~45 days, potentially enabling a prompt market clearance application.</li><li>Claims of superior retention, dosing and procedural safety versus other delivery modalities, which could strengthen commercial value if approved.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Pre-Submission is not an approval; FDA alignment or clearance is not guaranteed.</li><li>Timelines are forward-looking and subject to regulatory and clinical risk.</li><li>Company explicitly disclaims obligation to update forward-looking statements; actual outcomes may differ materially.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/ca679aac-1712-4849-963d-39b43a390f2b" target="_blank">Original Article</a>
    </div>

    <div class="small">BCDA • TradersLink AI News</div>
  </div>
</body>
</html>